TITLE

Pregnancy with prosthetic heart valves — 30 years’ nationwide experience in Denmark

AUTHOR(S)
Sillesen, Martin; Hjortdal, Vibeke; Vejlstrup, Niels; Sørensen, Keld
PUB. DATE
August 2011
SOURCE
European Journal of Cardio-Thoracic Surgery;Aug2011, Vol. 40 Issue 2, p448
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract: Objective: Pregnancy in women with prosthetic heart valves remains a risk factor for both mother and fetus, but unselected and unbiased outcome and complication data remain scarce. We analyzed nationwide outcome data from 1977 to 2007 for all pregnancies in women with prosthetic valves. Methods: Cardiac, obstetric, and neonatal data were obtained from obligatory databases and compared with general female population data. Questionnaires were used to corroborate important information. Outcome data were analyzed according to type of anticoagulation used. The data were compared between the two first and the last decades of the study period. In the last decade, patients were compared to an age-adjusted selected population of healthy, pregnant women. Results: Of 356 women between 15 and 40 years of age, 79 women had 155 pregnancies after valve replacement. Two women died during pregnancy, one from heart failure and one from post-partum bleeding. There were four thrombo-embolic episodes in the early study period in women with mitral prosthesis on unfractionated heparin. Important cardiac complications were otherwise almost absent. There were significantly more early miscarriages and terminations in patients compared with controls (last decade 34%, vs 20% (p =0.0036) and 26% vs 13% (p =0.000019)). Post-partum bleeding was more common in the patient group (p =0.0021). Two late fetal losses (one from intracerebral bleeding) were seen. The remaining pregnancies resulted in 60 live births. Cesarean section was the predominant method of delivery in patients as opposed to controls (55% vs 16%, p =0.000000000097). Premature births were more frequent in patients (49% vs 5.5%, p =0.00000000039) as were congenital malformations (14% vs 5.7%, p =0.044). Two of the six malformations were warfarin embryopathy (8% of all first-trimester warfarin exposures), both seen in high-risk patients on high warfarin dosing. Small for gestational age did not differ significantly from the general population (9.3% vs 6.0%, p =0.39). Conclusion: Data acquired over 30 years confirm that women with prosthetic heart valves, especially aortic prostheses for congenital lesions, generally tolerate pregnancy well, although cardiac mortality, mortality related to anticoagulation and thrombo-embolic risks are raised. Our data provide further documentation on the significance and importance of the risks associated with predominantly warfarin-based treatment regimens, which still remains optional for a number of patients. Finally, the data also serve as a comparison for recently published series based on low-molecular-weight heparin (LMWH) regimens.
ACCESSION #
62844814

 

Related Articles

  • Severe Valvular Regurgitation: An Unexpected Complication During Transapical Aortic Valve Implantation Treated Successfully with the "Valve-in-Valve" Procedure. Mehmet Burgazlı, Kamil; Kavukcu, Ethem; Chasan, Ridvan; Bilgin, Mehmet; Erdoğan, Ali // Balkan Medical Journal;Dec2012, Vol. 29 Issue 4, p444 

    Severe symptomatic aortic stenosis (AS) in a multimorbid 77 year old female was treated with transapical aortic valve implantation with a 23 mm Edwards Sapien valve. Severe valvular regurgitation following implantation, probably due to structural valve failure, was treated successfully with a...

  • Paravalvular Leak Leading to Severe Aortic Valve Regurgitation after TAVI: Percutaneous Closure Strategy. Rossi, Marco Luciano; Belli, Guido; Pagnotta, Paolo; Lucarelli, Carla; Presbitero, Patrizia // Heart, Lung & Circulation;Sep2015, Vol. 24 Issue 9, p936 

    Regurgitation due to a paravalvular leak (PVL) is a complication that may affect patients undergoing surgical mechanical or bioprosthetic heart valve replacement. PVL can also occur after transcatheter aortic valve implantation (TAVI) in patients with severe aortic stenosis and is associated...

  • Anticoagulation of Pregnant Women with Mechanical Heart Valve Prosthesis: A Systematic Review of the Literature (2000-2009). Hassouna, Ahmed; Allam, Hemat // Journal of Coagulation Disorders;2010, Vol. 2 Issue 1, p1 

    Managing anticoagulation of pregnant women with mechanical heart valve prosthesis (MPHV) is now mainly limited to three alternatives: oral anticoagulants (OA) throughout pregnancy; oral anticoagulants substituted by heparin between the 6th and 12th week of gestation then resumed thereafter...

  • COUMARIN EMBRYOPATHY: AN OBSTETRICIAN'S PERSPECTIVE. Banerjee, Ananya; Prateek, Shashi // Indian Obstetrics & Gynaecology;2011, Vol. 1 Issue 3, p20 

    The article discusses a study concerning the use of coumarin derivatives in women with prosthetic heart valves and thrombotic states and its potential to cause fetal hemorrhage and teratogenicity. Topics include the incidence of patients on coumarins during pregnancy, therapeutic considerations...

  • Pregnancy in patients with prosthetic heart valves. Oakley, Celia // British Medical Journal (Clinical Research Edition);5/28/1983, Vol. 286 Issue 6379, p1680 

    Focuses on the effects of pregnancy on patients with prosthetic heart valves. Increase in the risk of thromboembolism; Effects in the usage of coumarin anticoagulants in pregnancy; Safeness of heparin.

  • Anticoagulant Therapy of Pregnant Patients with Prosthetic Heart Valves: Rationale for a Clinical Trial of Low Molecular Weight Heparin. Messmore Jr., Harry L.; Kundur, Ramesh; Wehrmacher, William; Scanlon, Patrick // Clinical & Applied Thrombosis/Hemostasis;Apr1999, Vol. 5 Issue 2, p73 

    The management of anticoagulant therapy for the prevention of thromboembolism from prosthetic heart valves in the pregnant patient is far from ideal and deserves more clinical research. Warfarin therapy given alone throughout pregnancy poses high risks to the fetus because it crosses the...

  • Mechanical Aortic Valve Without Anticoagulation For Twenty-Six Years. Ozler, Azmi; Dumantepe, Mert; Tarhan, Arif; Atalan, Korkut; Denizalt, Tark // Internet Journal of Thoracic & Cardiovascular Surgery;2013, Vol. 16 Issue 1, p1 

    Objective: Mechanical valvular prostheses have the advantage of longevity but carry a risk of thrombosis, which is dependent from valve design, materials and host-related interface. Anticoagulation is known as essential for mechanical heart valves to prevent lethal complications such as valve...

  • Implications of Using Different Methods to Characterise Anticoagulant Control in Patients with Second Generation Mechanical Heart Valve Prostheses. Fiorentino, Francesca; Rogers, Chris A.; Bryan, Alan J.; Angelini, Gianni D.; Reeves, Barnaby C. // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Objective: Characterisation of anticoagulant control is fundamental to investigations of its association with clinical outcome. Anticoagulant control depends on several factors. This paper aims to illustrate the implications of different methods for measuring and analysing anticoagulant control...

  • Long-term tricuspid valve prosthesis-related complications in patients with congenital heart disease. van Slooten, Ymkje J.; Freling, Hendrik G.; van Melle, Joost P.; Mulder, Barbara J.M.; Jongbloed, Monique R.M.; Ebels, Tjark; Voors, Adriaan A.; Pieper, Petronella G. // European Journal of Cardio-Thoracic Surgery;Jan2014, Vol. 45 Issue 1, p83 

    OBJECTIVES In patients with acquired valvar disease, morbidity and mortality rates after tricuspid valve replacement (TVR) are high. However, in adult patients with congenital heart disease, though data concerning outcome after TVR are scarce, even poorer results are suggested in patients with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics